Eli Lilly

Eli Lilly Genetic Medicine Push Expands with Ascidian Deal

Yuvraj — Fri, 05 Jun 2026 13:28:49 +0000

Eli Lilly has entered into a research collaboration with Ascidian Therapeutics aimed at discovering and developing treatments for kidney diseases, marking another step in the company’s ongoing genetic medicine strategy. The agreement, which could be worth up to $1.9bn for the Massachusetts-based biotechnology company, will initially focus on therapies targeting kidney disorders linked to a single […]

The post Eli Lilly Genetic Medicine Push Expands with Ascidian Deal first appeared on World Pharma Today.

Lilly Signs $1.26bn Sonefpeglutide Licensing Deal with Hanmi

Yuvraj — Tue, 02 Jun 2026 09:11:11 +0000

Eli Lilly and Company and Hanmi Pharm have officially finalized a comprehensive licensing agreement. Under the terms of the worldwide arrangement, Sonefpeglutide licensing is for global development, manufacturing, and commercialization, excluding the South Korean market. The financial framework includes a $75 million upfront payment to Hanmi, with the potential for up to $1.185 billion in […]

The post Lilly Signs $1.26bn Sonefpeglutide Licensing Deal with Hanmi first appeared on World Pharma Today.

Eli Lilly Returns to Infectious Disease with $3.8 Billion Acquisition Strategy

Yuvraj — Wed, 27 May 2026 05:29:27 +0000

After a seven-year absence from the sector, Eli Lilly is returning to the field through a trio of corporate purchases valued at more than $3.8 billion. This infectious disease M&A activity secures Curevo, LimmaTech Biologics, and Vaccine Company, firmly positioning the pharmaceutical organization within the vaccine development arena. The transactions represent a deliberate return to […]

The post Eli Lilly Returns to Infectious Disease with $3.8 Billion Acquisition Strategy first appeared on World Pharma Today.

Eli Lilly Kelonia Acquisition Advances in $2B Deal Talks

Yuvraj — Tue, 21 Apr 2026 05:47:56 +0000

Eli Lilly and Company is in advanced discussions to acquire Kelonia Therapeutics for more than $2 billion, according to a report by The Wall Street Journal. The report, citing people familiar with the matter, indicates that a deal could be finalized as early as Monday and may include additional payments tied to the achievement of […]

The post Eli Lilly Kelonia Acquisition Advances in $2B Deal Talks first appeared on World Pharma Today.

Eli Lilly to Acquire Centessa Pharmaceuticals in $7.8B Deal

Yuvraj — Fri, 03 Apr 2026 08:47:22 +0000

Eli Lilly & Co. is set to acquire Centessa Pharmaceuticals Plc in a transaction worth up to $7.8 billion, underscoring its push to broaden its drug development pipeline. The Centessa Pharmaceuticals deal highlights the company’s effort to expand into therapeutic areas beyond its current core focus, particularly within neuroscience. Under the terms announced Tuesday, Lilly will […]

The post Eli Lilly to Acquire Centessa Pharmaceuticals in $7.8B Deal first appeared on World Pharma Today.

Lilly, Insilico Sign $2.75B AI Drug Discovery Collaboration

Yuvraj — Mon, 30 Mar 2026 12:04:56 +0000

Eli Lilly has expanded its engagement with Insilico Medicine, formalising a new AI drug discovery collaboration valued at up to $2.75 billion, further extending a relationship that began with an AI software licensing agreement in 2023. The latest agreement follows a $100 million partnership signed in November 2025 and is designed to broaden the company’s […]

The post Lilly, Insilico Sign $2.75B AI Drug Discovery Collaboration first appeared on World Pharma Today.

Lilly Launches New AI Supercomputer for Drug Development

Yuvraj — Mon, 02 Mar 2026 13:45:04 +0000

Eli Lilly has launched what it describes as the most powerful AI factory wholly owned and operated by a pharmaceutical company, marking a significant expansion of advanced computing infrastructure in life sciences. The system, named LillyPod, was inaugurated in Indianapolis and is built as the world’s first NVIDIA DGX SuperPOD with DGX B300 systems, powered […]

The post Lilly Launches New AI Supercomputer for Drug Development first appeared on World Pharma Today.

Lilly Zepbound-Taltz Combo Gains Ground with Phase 3b Data

Yuvraj — Thu, 19 Feb 2026 09:29:18 +0000

Eli Lilly said that its weight-loss medicine Zepbound, when used in combination with psoriasis treatment Taltz, delivered stronger outcomes than Taltz alone in patients living with both psoriasis and obesity in a late-stage study. The psoriasis trial enrolled 274 patients and evaluated whether the addition of Zepbound could enhance both dermatologic and weight-loss outcomes. After […]

The post Lilly Zepbound-Taltz Combo Gains Ground with Phase 3b Data first appeared on World Pharma Today.

Weight-Loss Pills Mark a Turning Point for Pharma Industry

Yuvraj — Mon, 16 Feb 2026 11:58:02 +0000

The global pharmaceutical industry is entering a pivotal phase in obesity therapeutics as companies accelerate the transition from injectable GLP-1 drugs to oral weight-loss treatments, a shift expected to significantly expand patient access, alter reimbursement dynamics, and intensify competitive pressures in one of the fastest-growing drug categories. The commercial success of GLP-1 receptor agonists such […]

The post Weight-Loss Pills Mark a Turning Point for Pharma Industry first appeared on World Pharma Today.

Lilly Buys Orna for $2.4bn to Advance In Vivo Therapies

Yuvraj — Wed, 11 Feb 2026 09:50:59 +0000

Eli Lilly has agreed to acquire in vivo CAR-T developer Orna Therapeutics in a deal worth up to $2.4 billion, marking another rapid move to strengthen its research pipeline. The transaction positions Lilly buys Orna for $2.4bn as a strategic step into next-generation cell therapies delivered directly inside the body. Watertown, Massachusetts-based Orna is developing […]

The post Lilly Buys Orna for $2.4bn to Advance In Vivo Therapies first appeared on World Pharma Today.